Poor long-term outcome in patients with porto-sinusoidal vascular disease (PSVD): fact or disease misclassification?

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-11-27 DOI:10.1016/j.jhep.2024.11.031

Pierre-Emmanuel Rautou, Heloïse Giudicelli-Lett, Marta Magaz, Juan Carlos García-Pagán

{"title":"Poor long-term outcome in patients with porto-sinusoidal vascular disease (PSVD): fact or disease misclassification?","authors":"Pierre-Emmanuel Rautou, Heloïse Giudicelli-Lett, Marta Magaz, Juan Carlos García-Pagán","doi":"10.1016/j.jhep.2024.11.031","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors´ contributions:</h2>Pierre-Emmanuel Rautou and Juan Carlos García-Pagán wrote the letter. Marta Magaz and Heloïse Giudicelli-Lett critically revised the manuscript</section></section><section><section><h2>Financial support statement:</h2>PE Rautou’s research laboratory is supported by the Fondation pour la Recherche Médicale (FRM EQU202303016287), “Institut National de la Santé et de la Recherche Médicale” (ATIP AVENIR), the “Agence Nationale pour la Recherche” (ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, ANR-22-CE14-0002) by « Émergence, Ville de Paris », by Fondation ARC and by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847949.JC Garcia-Pagan’s research laboratory is</section></section><section><section><h2>Declaration of Competing Interest:</h2>JCGP: advisory for GORE, Cook and grant from Mallinckrodt and Astra-Zeneca.PER: research funding from Terrafirma; as consultant for Mursla, Genfit, Boehringer Ingelheim and Abbelight; speaker fees from AbbVie.The remaining authors declare no conflicts of interest that pertain to this work.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"8 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.11.031","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Authors´ contributions:

Pierre-Emmanuel Rautou and Juan Carlos García-Pagán wrote the letter. Marta Magaz and Heloïse Giudicelli-Lett critically revised the manuscript

Financial support statement:

PE Rautou’s research laboratory is supported by the Fondation pour la Recherche Médicale (FRM EQU202303016287), “Institut National de la Santé et de la Recherche Médicale” (ATIP AVENIR), the “Agence Nationale pour la Recherche” (ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, ANR-22-CE14-0002) by « Émergence, Ville de Paris », by Fondation ARC and by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847949.JC Garcia-Pagan’s research laboratory is

Declaration of Competing Interest:

JCGP: advisory for GORE, Cook and grant from Mallinckrodt and Astra-Zeneca.PER: research funding from Terrafirma; as consultant for Mursla, Genfit, Boehringer Ingelheim and Abbelight; speaker fees from AbbVie.The remaining authors declare no conflicts of interest that pertain to this work.

查看原文本刊更多论文

门静脉血管疾病（PSVD）患者的长期预后不佳：是事实还是疾病分类错误？

章节片段作者贡献：Pierre-Emmanuel Rautou 和 Juan Carlos García-Pagán 撰写了这封信。Marta Magaz 和 Heloïse Giudicelli-Lett 对手稿进行了严格的修改：PE Rautou 的研究实验室得到了医学研究基金会（FRM EQU202303016287）、"国家健康与医学研究机构"（ATIP AVENIR）、"国家研究机构"（ANR-18-CE14-0006-01.X）、"国家健康与医学研究机构"（ATIP AVENIR）、"国家健康与医学研究机构"（ANR-18-CE14-0006-01.X）和 "国家健康与医学研究机构"（ATIP AVENIR）的支持、RHU QUID-NASH、ANR-18-IDEX-0001、ANR-22-CE14-0002）、"Émergence, Ville de Paris"、ARC 基金会以及欧盟 "地平线 2020 "研究与创新计划（赠款协议编号 847949）。JC Garcia-Pagan 的研究实验室是竞争利益声明：JCGP：为 GORE、Cook 提供顾问服务，并从 Mallinckrodt 和 Astra-Zeneca 获得资助。PER：从 Terrafirma 获得研究资助；担任 Mursla、Genfit、Boehringer Ingelheim 和 Abbelight 的顾问；从 AbbVie 获得演讲费。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.